Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2024 Conference Call. Currently all participants are in a listen-only mode.
Cash, Cash Equivalents, and Marketable Securities: $134.6 million at the end of 2024.Net Cash Used in Operating Activities: $19.3 million for Q4 2024, down fro
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 31.25% and 154.92%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-neg
Revenue: Reported $7.68 million for the fourth quarter, meeting the estimated revenue of $7.68 million.Earnings Per Share (EPS): Reported EPS of -$0.15, meetin
Mersana Therapeutics Inc (MRSN) is set to release its Q4 2024 earnings on March 3, 2025. The consensus estimate for Q4 2024 revenue is $7.67 million, and the ea
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. ( MRSN), a clinical-stage biopharmaceutical company focused on discovering and
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. ( MRSN), a clinical-stage biopharmaceutical company focused on discovering and